featured
PIK3CA and MAP3K1 Are Associated With Clinical Benefit From Buparlisib + Letrozole in ER+ MBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
NPJ Breast Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
PIK3CA and MAP3K1 Alterations Imply Luminal A Status and Are Associated With Clinical Benefit From Pan-PI3K Inhibitor Buparlisib and Letrozole in ER+ Metastatic Breast Cancer
NPJ Breast Cancer 2019 Sep 01;[EPub Ahead of Print], MJ Nixon, L Formisano, IA Mayer, MV Estrada, PI González-Ericsson, SJ Isakoff, A Forero-Torres, H Won, ME Sanders, DB Solit, MF Berger, LC Cantley, EP Winer, CL Arteaga, JM BalkoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.